Alessandra Larocca - Dissemin

Language
Login

All papers authored by Alessandra Larocca

This paper is made freely available by the publisher.

2022 Mattia D'Agostino

ORCID

, David A. Cairns

ORCID

, Juan José Lahuerta

ORCID

, Ruth Wester, Uta Bertsch

ORCID

ORCID

, Elena Zamagni

ORCID

, María-Victoria Mateos

ORCID

, Daniele Dall'Olio

ORCID

, Niels W. C. J. van de Donk, Graham Jackson

ORCID

, Serena Rocchi, Hans Salwender

ORCID

, Joan Bladé Creixenti, Bronno van der Holt

ORCID

and 16 other authors

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

2021 Roberto Mina

ORCID

, Antonietta Pia Falcone, Sara Bringhen

ORCID

, Anna Marina Liberati

ORCID

, Norbert Pescosta, Maria Teresa Petrucci, Giovannino Ciccone, Andrea Capra, Francesca Patriarca, Delia Rota-Scalabrini, Francesca Bonello, Caterina Musolino, Michele Cea

ORCID

, Renato Zambello

ORCID

, Paola Tacchetti and 13 other authors

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial

Upload

This paper was not found in any repository, but could be made available legally by the author.

Alessandra Larocca

ORCID

, Xavier Leleu, Cyrille Touzeau

ORCID

, Joan Bladé, Agne Paner, María‐Victoria Mateos

ORCID

, Michele Cavo, Christopher Maisel, Adrían Alegre, Albert Oriol, Anastasios Raptis, Paula Rodriguez‐Otero

ORCID

, Amitabha Mazumder, Jacob Laubach

ORCID

, Omar Nadeem and 5 other authors

Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Alessandra Larocca

ORCID

, Francesca Bonello, Gianluca Gaidano

ORCID

, Mattia D’Agostino, Massimo Offidani, Nicola Cascavilla, Andrea Capra, Giulia Benevolo

ORCID

, Patrizia Tosi, Monica Galli, Roberto Marasca

ORCID

, Nicola Giuliani, Annalisa Bernardini, Elisabetta Antonioli, Delia Rota-Scalabrini and 9 other authors

Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma

Upload

This paper is made freely available by the publisher.

Evangelos Terpos

ORCID

, Joseph Mikhael, Roman Hajek

ORCID

, Ajai Chari, Sonja Zweegman, Hans C. Lee, Lee Hc, María-Victoria Mateos

ORCID

, Mateos Mv, Alessandra Larocca

ORCID

, Karthik Ramasamy, Martin Kaiser

ORCID

ORCID

, Katja C. Weisel

ORCID

, Weisel Kc and 6 other authors

Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

Download from www.nature.com

This paper is made freely available by the publisher.

2020 Mattia D'Agostino, Gian Maria Zaccaria

ORCID

, Bachisio Ziccheddu, Even H. Rustad

ORCID

, Elisa Genuardi

ORCID

, Andrea Capra, Stefania Oliva

ORCID

, Daniel Auclair, Jennifer Yesil, Paola Colucci, Jonathan J. Keats

ORCID

, Manuela Gambella, Sara Bringhen, Alessandra Larocca

ORCID

, Mario Boccadoro and 3 other authors

Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing

Download from aacrjournals.org

This paper was not found in any repository, but could be made available legally by the author.

Vincenzo Apolito, Luisa Giaccone, Simone Ferrero, Alessandra Larocca

ORCID

, Federica Cavallo, Marta Coscia, Eloise Beggiato, Sara Butera, Federica Martella, Cristina Dainese, Giusy Cetani, Matilde Scaldaferri, Francesco Cattel, Mario Boccadoro, Dario Ferrero and 2 other authors

Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation

Upload

This paper is made freely available by the publisher.

Gordon Cook

ORCID

, Alessandra Larocca

ORCID

, Thierry Facon, Sonja Zweegman, Monika Engelhardt

Defining the vulnerable patient with myeloma—a frailty position paper of the European Myeloma Network

Download from www.nature.com

This paper was not found in any repository, but could be made available legally by the author.

Roberto Mina

ORCID

, Angelo Belotti, Maria Teresa Petrucci, Renato Zambello, Andrea Capra, Giacomo Di Lullo, Sonia Ronconi, Norbert Pescosta, Mariella Grasso, Federico Monaco, Claudia Cellini, Marco Gobbi, Stelvio Ballanti, Paolo de Fabritiis, Maria Letizia Mosca-Siez and 10 other authors

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study

Upload

This paper is made freely available by the publisher.

Paolo Milani

ORCID

, Francesca Fazio, Marco Basset

ORCID

, Tamara Berno, Alessandra Larocca

ORCID

, Andrea Foli, Marcello Riva, Francesca Benigna, Stefania Oliva

ORCID

, Mario Nuvolone, Lara Rodigari, Maria Teresa Petrucci, Giampaolo Merlini, Giovanni Palladini

High rate of profound clonal and renal responses with daratumumab treatment in heavily pre‐treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate

Download from api.wiley.com

This paper was not found in any repository, but could be made available legally by the author.

Katja Weisel, Meletios Dimopoulos

ORCID

, Philippe Moreau, Munci Yagci, Alessandra Larocca

ORCID

, Abraham S. Kanate, Filiz Vural, Nicola Cascavilla, Supratik Basu, Peter Johnson, Peter Byeff, Marek Hus, Paula Rodríguez-Otero, Ercan Muelduer, Pekka Anttila and 11 other authors

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

Upload

This paper is made freely available by the publisher.

Stefania Oliva

ORCID

, Mattia D'Agostino, Mario Boccadoro, Alessandra Larocca

ORCID

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma

Download from doi.org

This paper is made freely available by the publisher.

2019 Sara Bringhen, Mattia D'Agostino, Mattia D’Agostino, Laura Paris, Stelvio Ballanti, Norbert Pescosta, Stefano Spada, Sara Pezzatti, Mariella Grasso, Delia Rota-Scalabrini, Luca De Rosa, Vincenzo Pavone, Giulia Gazzera, Sara Aquino, Marco Poggiu and 12 other authors

Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

Saad Zafar Usmani, Fredrik Schjesvold, Albert Oriol, Lionel Karlin, Michele Cavo

ORCID

, Robert M. Rifkin, Habte Aragaw Yimer, Richard LeBlanc, Naoki Takezako, Robert Donald McCroskey, Andrew Boon Ming Lim, Kenshi Suzuki, Hiroshi Kosugi, George Grigoriadis, Irit Avivi and 92 other authors

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Upload

This paper was not found in any repository, but could be made available legally by the author.

Maria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, Albert Oriol, David Simpson, Anupkumar George, Hartmut Goldschmidt, Alessandra Larocca

ORCID

, Asher Chanan-Khan, Daniel Sherbenou, Irit Avivi, Noam Benyamini, Shinsuke Iida, Morio Matsumoto, Kenshi Suzuki and 92 other authors

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

Upload

This paper is made freely available by the publisher.

Alessandra Larocca

ORCID

ORCID

, Massimo Offidani, Anna Marina Liberati, Antonio Ledda, Francesca Patriarca, Andrea Evangelista, Stefano Spada, Giulia Benevolo, Daniela Oddolo, Vanessa Innao, Clotilde Cangialosi, Clotilde Cangiolosi, Annalisa Bernardini, Pellegrino Musto and 13 other authors

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

Paul G. Richardson, Albert Oriol, Meral Beksac, Anna Marina Liberati, Monica Galli, Fredrik Schjesvold, Jindriska Lindsay, Katja Weisel, Darrell White, Thierry Facon, Jesus San Miguel, Kazutaka Sunami, Peter O'Gorman, Pieter Sonneveld, Pawel Robak and 150 other authors

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Upload

This paper was not found in any repository, but could be made available legally by the author.

S. Bringhen

ORCID

, A. Milan, M. D'Agostino, C. Ferri, R. Wäsch, F. Gay

ORCID

, A. Larocca

ORCID

, M. Offidani, S. Zweegman, E. Terpos, H. Goldschmidt, M. Cavo

ORCID

, H. Ludwig, C. Driessen, H. W. Auner and 7 other authors

Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension

Upload

This paper was not found in any repository, but could be made available legally by the author.

Sonja Zweegman, Alessandra Larocca

ORCID

Frailty in multiple myeloma: the need for harmony to prevent doing harm

Upload

This paper is made freely available by the publisher.

Sara Bringhen, Roberto Mina

ORCID

, Maria Teresa Petrucci, Gianluca Gaidano, Stelvio Ballanti, Pellegrino Musto, Massimo Offidani, Stefano Spada, Giulia Benevolo, Elena Ponticelli, Piero Galieni, Michele Cavo

ORCID

, Tommaso Caravita Di Toritto, Francesco Di Raimondo, Vittorio Montefusco and 3 other authors

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies

Download from doi.org

Missing publications? Search for publications with a matching author name.